公开(公告)号：US20200261444A1

公开(公告)日：2020-08-20

申请号：US16347194

申请日：2017-11-01

Applicant: NOVARTIS AG

Inventor： Robin Alec FAIRHURST ,  Diana GRAUS PORTA ,  Jacqueline KINYAMU-AKUNDA ,  Andreas Joerg MAHL ,  Luigi MANENTI ,  Andreas WEISS ,  Armin WOLF ,  Kuno WUERSCH

IPC: A61K31/496 ,  A61K31/14

Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.

公开(公告)号：US20230293529A1

公开(公告)日：2023-09-21

申请号：US17999694

申请日：2021-05-25

Applicant: Novartis AG

Inventor： Yi GU ,  Sebastien JEAY ,  Yi JIN ,  Marc LAISNEY ,  Christophe MEILLE ,  Prakash Dahyabhai MISTRY ,  Jonathan Guy MOGGS ,  Andreas WEISS ,  Mélanie Monique Laura WILBAUX

IPC: A61K31/519 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61P35/00

Abstract: The invention provided herein provides dosage and dosage regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (Compound (1)), or a pharmaceutically acceptable salt thereof, Compound (1) for the treatment of PRC2-mediated diseases or disorders. In addition, the invention provides using such dosage and dosage regimens in methods for treating PRC2-mediated diseases or disorders.

公开(公告)号：US20190231760A1

公开(公告)日：2019-08-01

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNOPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20240366567A1

公开(公告)日：2024-11-07

申请号：US18572518

申请日：2022-06-23

Applicant: NOVARTIS AG

Inventor： Saskia Maria BRACHMANN ,  Simona COTESTA ,  Xiaoming CUI ,  Ruben DE KANTER ,  Anna FARAGO ,  Marc GERSPACHER ,  Diana GRAUS PORTA ,  Jaeyeon KIM ,  Catherine LEBLANC ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Christophe MURA ,  Pascal RIGOLLIER ,  Anirudh Cadapa PRAHALLAD ,  Nadine SCHNEIDER ,  Rowan STRINGER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Andreas WEISS

IPC: A61K31/416 ,  A61K31/519 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22

Abstract: The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pharmaceutical compositions comprising the same. The invention also relates to KRAS G12C inhibitors alone or said combinations for use in methods of treating a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutant.

公开(公告)号：US20240082218A1

公开(公告)日：2024-03-14

申请号：US18267735

申请日：2021-12-20

Applicant: NOVARTIS AG

Inventor： Vasileios ASKOXYLAKIS ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Xiaoming CUI ,  Jeffrey ENGELMAN ,  Anna FARAGO ,  Marc GERSPACHER ,  Diana GRAUS PORTA ,  Catherine LEBLANC ,  Edwige Liliane Jeanne LORTHIOIS ,  Bo LIU ,  Rainer MACHAUER ,  Robert MAH ,  Christophe MURA ,  Pascal RIGOLLIER ,  Nadine SCHNEIDER ,  Stefan STUTZ ,  Andrea Helga Emmi VAUPEL ,  Nicolas WARIN ,  Andreas WEISS ,  Rainer WILCKEN ,  Padmaja YERRAMILLI-RAO

IPC: A61K31/416 ,  A61K9/00 ,  A61K31/497 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K9/0053 ,  A61K31/497 ,  A61K39/3955 ,  A61P35/00

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.

公开(公告)号：US20180185341A1

公开(公告)日：2018-07-05

申请号：US15516443

申请日：2015-10-02

Applicant: Novartis AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNÖPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61K31/496 ,  A61P35/00

CPC classification number: A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof